SPRC vs. SBFM, EVFM, HSTO, EVLO, BLPH, CMRA, LSDI, ADTX, GRI, and SXTC
Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Sunshine Biopharma (SBFM), Evofem Biosciences (EVFM), Histogen (HSTO), Evelo Biosciences (EVLO), Bellerophon Therapeutics (BLPH), Comera Life Sciences (CMRA), Lucy Scientific Discovery (LSDI), Aditxt (ADTX), GRI Bio (GRI), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical preparations" industry.
Sunshine Biopharma (NASDAQ:SBFM) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
SciSparc received 1 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 66.67% of users gave SciSparc an outperform vote.
Sunshine Biopharma has higher revenue and earnings than SciSparc.
Sunshine Biopharma has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Sunshine Biopharma presently has a consensus price target of $260.00, suggesting a potential upside of 26,430.61%. Given SciSparc's higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than SciSparc.
SciSparc has a net margin of 0.00% compared to SciSparc's net margin of -18.70%. Sunshine Biopharma's return on equity of 0.00% beat SciSparc's return on equity.
In the previous week, Sunshine Biopharma had 3 more articles in the media than SciSparc. MarketBeat recorded 3 mentions for Sunshine Biopharma and 0 mentions for SciSparc. SciSparc's average media sentiment score of 0.10 beat Sunshine Biopharma's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.
42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 4.1% of Sunshine Biopharma shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Sunshine Biopharma beats SciSparc on 10 of the 15 factors compared between the two stocks.
Get SciSparc News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SciSparc Competitors List
Related Companies and Tools
